Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse PD-L1 Monoclonal Antibodies

Anti-Mouse PD-L1 Monoclonal Antibodies

Name: Anti-Mouse PD-L1 Monoclonal Antibodies
Brand: Syd Labs
SKU: PA007164.r2b
Price: 150.00 USD
Availability: InStock
Rating: 5 (10 reviews)

Programmed Death Ligand 1, B7-H1, CD274, 10F.9G2

Catalog No.	Product Name	Size	List Price (US$)
PA007164.r2b	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Rat IgG2b Kappa	1 mg	150.00
PA007164.r2b	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Rat IgG2b Kappa	5 mg	275.00
PA007164.r2b	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Rat IgG2b Kappa	25 mg	900.00
PA007164.m2cLA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa	1 mg	150.00
PA007164.m2cLA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa	5 mg	275.00
PA007164.m2cLA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa	25 mg	900.00
PA007164.m2aLA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa	1 mg	150.00
PA007164.m2aLA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa	5 mg	275.00
PA007164.m2aLA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa	25 mg	900.00
PA007164.m1DA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG1-D265A Kappa	1 mg	160.00
PA007164.m1DA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG1-D265A Kappa	5 mg	400.00
PA007164.m1DA	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG1-D265A Kappa	25 mg	1100.00
PA007164.m2b	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2b Kappa	1 mg	150.00
PA007164.m2b	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2b Kappa	5 mg	400.00
PA007164.m2b	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2b Kappa	25 mg	1100.00
PA007164.rt	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Rabbit IgG	5 mg	595.00
PA007164.m2a	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG2a Kappa	5 mg	595.00
PA007164.m1	In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody (Clone 10F.9G2.1), Mouse IgG1 Kappa	5 mg	400.00

Note

Recombinant anti-mouse PD L1 / B7-H1 monoclonal antibodies, which share the same variable region sequences with the rat anti-mouse PD L1 monoclonal antibody (clone number: 10F.9G2), are produced from mammalian cells and good for in vitro and in vivo studies.
Note

Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Order Offline

Phone: 1-617-401-8149

Fax: 1-617-606-5019

Email: message@sydlabs.com

Or leave a message with a formal purchase

order (PO) Or credit card.

Description

Background

The rat anti-mouse PD-L1 monoclonal antibody 10F.9G2 (rat IgG2b kappa) reacts with the mouse PD-L1 protein (programmed death ligand-1, B7-H1 or CD274), a member of the B7 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2. It has been shown that in mouse models of melanoma, tumor growth can be transiently arrested via treatment with the anti-mouse PD-1 and anti-mouse PD-L1 antibodies which block the interaction between the PD-L1 protein and its receptor PD-1 protein. The 10F.9G2 monoclonal antibody blocks the binding of the mouse PD-L1 protein to the mouse PD-1 protein.

Our recombinant 10F.9G2 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse PD L1 monoclonal antibody (hybridoma clone name or number: 10F.9G2).

PA007164.m2cLA: In Vivo Grade Recombinant Anti-mouse PD-L1 Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa Monoclonal Antibody (Clone 10F.9G2.1)

The in vivo grade recombinant anti-mouse PD-L1 / B7-H1 monoclonal antibody (mouse IgG2c-LALAPG kappa) was produced in mammalian cells.
Immunogen: The original rat hybridoma (clone name: 10F.9G2) was generated by immunizing rats with the mouse PD-L1 cDNA and mouse PD-L1 CHO transfectants.
Clone: 10F.9G2.1, the same variable region sequences as the rat anti-mouse PD-L1 monoclonal antibody (clone number: 10F.9G2).
Isotype: mouse IgG2c, kappa.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007164.r2b: In Vivo Grade Recombinant Anti-mouse PD-L1 Rat IgG2b Kappa Monoclonal Antibody (Clone 10F.9G2.1)

The in vivo grade recombinant anti-mouse PD-L1 / B7-H1 monoclonal antibody (rat IgG2b kappa) was produced in mammalian cells.
Immunogen: The original rat hybridoma (clone name: 10F.9G2) was generated by immunizing rats with the mouse PD-L1 cDNA and mouse PD-L1 CHO transfectants.
Clone: 10F.9G2.1, the same variable region and constant region sequences as the rat anti-mouse PD-L1 monoclonal antibody (clone number: 10F.9G2).
Isotype: rat IgG2b, kappa.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse PD L1 / B7-H1 monoclonal antibodies are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

References of anti-mouse PD-L1 antibody (clone: 10F.9G2):

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
Kurino, T., et al. (2020). J Immunother Cancer. 2020 Feb;8(1):e000400. doi: 10.1136/jitc-2019-000400. PMID: 32041818
Antitumor activity of mAbs aPD-1 (IgG2a, RMP1-14) and aPD-L1 antibody (IgG2b, 10F.9G2) mAbs were employed in this study to evaluate antitumor activity. The early (3-hour) blood concentration of 10F.9G2 mAb (anti-mouse PD-L1 antibody) was approximately 20-fold lower than that of aPD-1 mAb (figure 4A), which indicated that 10F.9G2 mAb (anti-mouse PD-1) was distributed extensively in PD-L1-expressing tissues. As the blood concentration of the 10F.9G2 mAb approached zero, it was suggested that this aPD-L1 mAb (10F.9G2) was highly distributed throughout various organs at early time points, especially in the spleen, liver, and kidney (figure 4C). In contrast, the PK of 10F.9G2 mAb was strongly affected by the presence of excessive unlabeled mAbs. The blood concentration of 10F.9G2 mAb at 3 hours was comparable with that of aPD-1 mAb (figure 6A).
Kws: 10F.9G2 antibody; anti-mouse PD-L1 10F.9G2

Antibody-Dependent Cellular Cytotoxicity of Anti-Pd-L1 Antibodies for T Cells Attenuate Their Antitumor Efficacy in a Murine Tumor Model
Tamemoto, Y., et al. (2025). SSRN Electronic Journal. 2025; doi: 10.2139/ssrn.5157800. PMID: 40412452
We evaluated the significant determinants of the therapeutic efficacy of anti-programmed death-ligand 1 (aPD-L1) monoclonal antibodies (aPD-L1 mAbs, 10F.9G2) by comparing the differences in antibody-dependent cellular cytotoxicity (ADCC) activity of aPD-L1 mAbs (10F.9G2) of different isotypes (clones 10F.9G2 and MIH6). In MM48 tumor-bearing mice, MIH6 without ADCC activity inhibited tumor growth by more than 90%, whereas 10F.9G2 (anti-mouse PD-L1 antibody) with ADCC activity showed slight antitumor effect. The half-life and amount of intact form of aPD-L1 mAbs (10F.9G2) in tumors were 2.6- and 1.6-fold higher in MIH6 cells than in 10F.9G2 cells, respectively. Only 10F.9G2 (anti-mouse PD-L1 mAb) reduced the number of CD8+ T cells in MM48 tumor-bearing mice. The early (3-hour) blood concentration of 10F.9G2 mAb (10F.9G2) was approximately 20-fold lower than that of aPD-1 mAb (figure 4A), which indicated that 10F.9G2 mAb (10F.9G2) was distributed extensively in PD-L1-expressing tissues.
Kws: activity of anti-mouse PD-L1; anti-mouse PD-L1 (CD274)

PD-1 Specific ‘Blocking’ Antibodies That Deplete PD-1+ T Cells Present An Inconvenient Variable In Pre-clinical Immunotherapy Experiments
Polesso, F., et al. (2020). bioRxiv. 2020; doi: 10.1101/2020.04.14.041608. PMID: 33684223
We show here that anti-PD-1 clone G4 (hamster IgG), when compared to anti-PD-1 clone RMP1-14 (rat IgG2a), or anti-PD-L1 antibody clone 10F.9G2 (rat IgG2b), resulted in a loss of antigen-specific CD8 T cells in two sarcoma tumor models and the murine cytomegalovirus (MCMV) infection model. We then evaluated the frequency and total number of T cells in tumor-bearing animals treated with either anti-PD-1 (clone G4) or anti-PD-L1 antibody (clone 10F.9G2). In contrast, anti-PD-L1 (10F.9G2) treatment lead to an increase in total CD8 T cells as well as tumor specific T cells in the tumor (Fig 2H-J). On day 1 and 4 post infection, mice were treated with 200 ug of rat IgG, anti-PD-1 (G4), anti-PD-1 (RMP1-14), or anti-PD-L1 (10F.9G2) i.p. Moreover, there was a significant decrease in IFN g +M38-specific CD8 T cells after treatment with the PD-1 clone G4 but not with clone RMP1-14 or PD-L1 antibody (Fig 3E-F).
Kws: activity of anti-mouse PD-L1; activity of 10F.9G2 mAb

89 Zr Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
Jung, K. H., et al. (2020). J Nucl Med. 2021 May 10;62(5):656-664. doi: 10.2967/jnumed.120.250720. PMID: 32917780
Rat IgG against mouse PD-L1 (10F.9G2; BioXcell, West Lebanon, NH) was site-specifically conjugated with deferoxamine-maleimide on sulfohydryl residues. The monoclonal antibody used was a rat IgG2b (10F.9G2) that specifically binds to the extracellular domain of mouse PD-L1. Frozen tumor sections underwent overnight incubation at 4°C with a primary anti-mouse PD-L1 antibody (Abcam, #ab213480; 1:200). Specificity of uptake was assessed by 1 h pre-injection of a 5:1 molar ratio of cold anti-PD-L1 antibody over the radiotracer. Pre-injection of cold anti-PD-L1 caused a 66.1% reduction in CT26/PD-L1 tumor uptake, confirming specific uptake (Fig. 3A).
Kws: 10F.9G2 mAb for animal model; 10F.9G2 mAb in vivo

Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering
Zanello, A., et al. (2022). Front Pharmacol. 2022 Aug 16;13:972046. doi: 10.3389/fphar.2022.972046. PMID: 36052121
The most used is the anti-PD-L1 mAb clone 10F.9G2 (IgG2b), which was obtained by immunizing Lewis rats with murine PD-L1 cDNA and murine PD-L1 CHO transfectants (Paterson et al., 2011). The anti-PD-L1 mAb clone 10F.9G2 was used with the aim to elicit in vivo specific CD8+ cytotoxic T lymphocyte (CTL) response toward tumor. After administration to C57BL/6 mice bearing TC-1 (lung epithelial) cells, the conjugate generated a higher number of systemic and tumor-infiltrating E7-specific CTLs than those generated by E7 and 10F.9G2 administered either separately or in combination. The 10F.9G2 clone was conjugated to the NIR molecule IR700 (PD-L1-IR700) for photoimmunotherapy of ovarian cancer. IR700 was also conjugated to F(ab′)2 fragment of 10F.9G2; luciferase-expressing MC38 (murine colon cancer cells), LL/2 (murine Lewis lung carcinoma cells), and TRAMP-C2 (murine prostate cancer cell) cells were used to induce tumor in C57BL/6 mice.
Kws: anti-mouse PD-L1 10F.9G2 antibody in animal model; anti-mouse PD-L1 10F.9G2 in mouse tumor model

For more references about anti-mouse PD-L1 antibody (clone: 10F.9G2), please contact our scientific support team with message@sydlabs.com.

Recombinant PD1 and PDL1 Proteins:
Recombinant Human PD-1/PDCD1 Proteins
Biotinylated Recombinant Human PD-1/PDCD1 Proteins
Recombinant Mouse PD-1/PDCD1 Proteins
Biotinylated Recombinant Mouse PD-1/PDCD1 Proteins
Recombinant Cynomolgus PD-1/PDCD1 Proteins
Recombinant Canine PD-1/PDCD1 Proteins
Biotinylated Cynomolgus/Rhesus macaque PD-L1 Protein
Biotinylated Human PD-L1 Protein
Biotinylated Mouse PD-L1 Protein
Cynomolgus PD-L1 Protein
Cynomolgus/Rhesus macaque PD-L1 Protein
Human PD-L1/B7-H1 Protein
Mouse PD-L1/B7-H1 Protein

Questions and Answers about anti-mouse PD-L1 antibody (Clone 10F.9G2):

Question: Do you produce Fc-silenced 10F.9G2 antibody?
Answer: Sure, we provide various recombinant Fc slient 10F.9G2 antibodies, such as mIgG2c LALAPG, mIgG2a LALAPG, and mIgG1 D265A. We also provide custom recombinant antibody production service to produce other engineered versions of recombinant 10F.9G2 antibodies.

Question: What is the difference among PA007164.r2b and PA007164.m2cLA?
Answer: PA007164.r2b is the recombinant anti-mouse PD L1 monoclonal antibody (rat IgG2b kappa, clone 10F.9G2.1) produced in CHO cells or HEK293 cells if needed. It has the same variable region and constant region sequences as the rat anti-mouse PD-L1 monoclonal antibody from the hybridoma clone of 10F.9G2. Rat antibodies may cause high immuogenicity in mice; thus, at least recombinant antibodies with mouse antibody constant regions should be used to replace the rat antibody constant regions. PA007164.m2cLA is the recombinant anti-mouse PD-L1 antibody (clone 10F.9G2.1) whose constant regions are mouse IgG2c LALAPG kappa.

Home

Services

Molecular Biology

Proteins & Peptides

Antibodies

ELISA Kits

Chemicals

Cell Biology

Contact

My Syd Labs

Email Notifications